AnewPharma clinical trials

Acquired by Betta Pharmaceuticals Co., Ltd., Jun 15, 2017 · source ↗

The registry lists 14 studies whose lead sponsor is AnewPharma. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 14, 2022.

Studies

Recruiting first, then most recently updated. Showing 14 of 14. All Betta Pharmaceuticals Co., Ltd. studies →

• The Absorption, Metabolism and Excretion of [14C]CM082 in HumanCompletedNCT04434326Phase 1

  Sponsor listed in the registry: AnewPharma · First submitted after AnewPharma became part of Betta Pharmaceuticals Co., Ltd.

• Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid TumorsStatus unknownNCT03792958Phase 1

  Sponsor listed in the registry: AnewPharma · First submitted after AnewPharma became part of Betta Pharmaceuticals Co., Ltd.

• Bioequivalency Study of CM082 Tablet in Healthy VolunteersCompletedNCT04328506Phase 1

  Sponsor listed in the registry: AnewPharma · First submitted after AnewPharma became part of Betta Pharmaceuticals Co., Ltd.

• CM082 in Patients With Myopic Choroidal Neovascularization (CNV)SuspendedNCT04222842Phase 1

  Sponsor listed in the registry: AnewPharma · First submitted after AnewPharma became part of Betta Pharmaceuticals Co., Ltd.

• CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell CarcinomaStatus unknownNCT03095040Phase 3

  Sponsor listed in the registry: AnewPharma · First submitted before AnewPharma became part of Betta Pharmaceuticals Co., Ltd.

• CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)Status unknownNCT03904719Phase 2

  Sponsor listed in the registry: AnewPharma · First submitted after AnewPharma became part of Betta Pharmaceuticals Co., Ltd.

• CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).Status unknownNCT03848611Phase 2

  Sponsor listed in the registry: AnewPharma · First submitted after AnewPharma became part of Betta Pharmaceuticals Co., Ltd.

• A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy VolunteersCompletedNCT04126668Phase 1

  Sponsor listed in the registry: AnewPharma · First submitted after AnewPharma became part of Betta Pharmaceuticals Co., Ltd.

• Safety and Tolerability of Oral CM082 in Patients With wAMDStatus unknownNCT03710863Phase 2

  Sponsor listed in the registry: AnewPharma · First submitted after AnewPharma became part of Betta Pharmaceuticals Co., Ltd.

• Phase 1 Study of CM082 in Patients With wAMDSuspendedNCT02452385Phase 1

  Sponsor listed in the registry: AnewPharma · First submitted before AnewPharma became part of Betta Pharmaceuticals Co., Ltd.

• Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in ChinaCompletedNCT01863485Phase 1

  Sponsor listed in the registry: AnewPharma · First submitted before AnewPharma became part of Betta Pharmaceuticals Co., Ltd.

• Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.Status unknownNCT03602547Phase 2

  Sponsor listed in the registry: AnewPharma · First submitted after AnewPharma became part of Betta Pharmaceuticals Co., Ltd.

• Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric CancerStatus unknownNCT03286244Phase 1

  Sponsor listed in the registry: AnewPharma · First submitted after AnewPharma became part of Betta Pharmaceuticals Co., Ltd.

• Study of the Combination of CM082 With Everolimus in Patients With mRCCStatus unknownNCT02577458Phase 1

  Sponsor listed in the registry: AnewPharma · First submitted before AnewPharma became part of Betta Pharmaceuticals Co., Ltd.